Mainz Biomed B.V.
MYNZ
$-0.14
Change (1 day)
$7.95
Year High
$0.18
Year Low
Categories
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Earnings for Mainz Biomed B.V. (MYNZ)
Earnings in 2023 (TTM): $-26,295,727
According to Mainz Biomed B.V.'s latest financial reports the company's current earnings (TTM) are $-26,295,727. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Mainz Biomed B.V.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-26,295,727 | $-26,295,727 |
| 2022 | $-26,387,336 | $-26,452,725 |
| 2021 | $-11,695,158 | $-12,072,280 |
| 2020 | $-586,895 | $-886,177 |
| 2019 | $-957,055 | $-1,174,766 |